CeriBell’s (CBLL) “Buy” Rating Reiterated at BTIG Research

Posted by Stanley Muller on Sep 14th, 2026

BTIG Research restated their buy rating on shares of CeriBell (NASDAQ:CBLL – Free Report) in a report issued on Friday, MarketBeat reports. They currently have a $30.00 price target on the stock.

A number of other equities research analysts also recently weighed in on CBLL. Weiss Ratings downgraded shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 28th. Canaccord Genuity Group increased their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Raymond James Financial restated a “strong-buy” rating and set a $29.00 price objective on shares of CeriBell in a research report on Thursday, September 3rd. Finally, Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.40.

Get Our Latest Report on CBLL

CeriBell Price Performance

CBLL opened at $23.63 on Friday. CeriBell has a twelve month low of $10.85 and a twelve month high of $25.33. The company has a market capitalization of $906.92 million, a price-to-earnings ratio of -13.43 and a beta of 0.95. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. The firm has a 50-day moving average price of $21.11 and a 200-day moving average price of $19.63.

CeriBell (NASDAQ:CBLL – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The business had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. Equities analysts expect that CeriBell will post -1.96 EPS for the current year.

Insider Activity at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 39,540 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $24.61, for a total transaction of $973,079.40. Following the completion of the sale, the chief executive officer owned 767,191 shares of the company’s stock, valued at $18,880,570.51. This represents a 4.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP David Foehr sold 9,255 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $24.25, for a total transaction of $224,433.75. Following the completion of the sale, the vice president directly owned 34,144 shares in the company, valued at approximately $827,992. This trade represents a 21.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 391,901 shares of company stock worth $8,542,455 over the last ninety days. Insiders own 17.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CBLL. Russell Investments Group Ltd. lifted its holdings in CeriBell by 41.4% in the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after buying an additional 854 shares during the period. Sei Investments Co. grew its position in shares of CeriBell by 2.3% in the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after buying an additional 1,125 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares during the period. Deutsche Bank AG increased its stake in shares of CeriBell by 1.7% during the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after buying an additional 1,393 shares during the period. Finally, Strs Ohio bought a new position in shares of CeriBell during the first quarter valued at approximately $27,000.

CeriBell Company Profile

(Get Free Report)

Ceribell, Inc (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company’s primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.